Science and Technology Science and Technology
Sat, February 22, 2025
[ Sat, Feb 22nd ] - Yahoo
American Renaissance Man
Fri, February 21, 2025
[ Fri, Feb 21st ] - MSN
What's JD Vance's net worth?
[ Fri, Feb 21st ] - MSN
What is JD Vance's net worth?

NICE green lights two blood cancer therapies for NHS use


Published on 2025-02-21 15:02:36 - MSN
  Print publication without navigation

  • BMS' Breyanzi and Amgen's Blincyto will now be available to patients in England with certain types of blood cancer.

The UK's National Institute for Health and Care Excellence (NICE) has approved two new therapies, mosunetuzumab (Lunsumio) and glofitamab (Columvi), for treating specific types of blood cancer within the NHS. These treatments are targeted at adults with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior lines of systemic therapy. Mosunetuzumab is administered as a fixed course over 8 cycles, while glofitamab is given until disease progression or unacceptable toxicity. Both drugs work by engaging the body's immune system to attack cancer cells, offering a new hope for patients with this aggressive form of lymphoma. The approval follows a recommendation from NICE's Highly Specialised Technologies committee, highlighting the potential of these therapies to significantly improve patient outcomes.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/nice-green-lights-two-blood-cancer-therapies-for-nhs-use/ar-AA1zxweQ ]